Bristol-Myers Squibb stock heads into the open after a 1.0 percent dip
Published on 09/11/2026 at 05:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol-Myers Squibb stock closed at USD 63.75 on the NYSE on September 10, 2026, down 1.02 percent from the previous session per exchange data cited by finance portals. Compared with a modest decline in the S&P 500 on the same date, the shares underperformed the broad market by a small margin. Today, investors focus on recent option activity and updated analyst views that could influence Bristol-Myers Squibb stock into the open.
September 10, 2026 in numbers
Bristol-Myers Squibb Co. (ISIN US1078421011, NYSE: BMY) traded down to a close of USD 63.76 on September 10, 2026, with intraday moves broadly consistent with the reported official settlement of USD 63.75 on the NYSE for that session. According to a performance wrap on Yahoo Finance, the stock slipped 1.02 percent on September 10, 2026, mirroring a softer tone in healthcare shares but falling slightly more than the wider market. A same-day overview from MarketBeat noted trading volume of 3,869,938 shares for NYSE:BMY on September 10, 2026, against an average volume close to 11.9 million shares, indicating a quieter session in terms of turnover even as the price eased.
In the same MarketBeat snapshot, Bristol-Myers Squibb shares were described as trading between a one year low of USD 42.52 and a one year high of USD 68.64, placing the September 10, 2026 close nearer the upper half of that 52-week range. While exact intraday high and low values for that session were not highlighted in the report, the relationship between the closing level and the 52-week markers shows the stock still retaining a substantial gain relative to its trough of the past year. Separately, a broader valuation and performance piece from Yahoo Finance on September 10, 2026 pointed out that Bristol-Myers Squibb shares had gained 19.4 percent year to date as of that report, outpacing an approximately 6.3 percent advance for the large-cap pharma industry, which provides additional context for the latest single-session pullback.
Today’s catalysts for Bristol-Myers Squibb
Looking at today, September 11, 2026, options positioning and analyst commentary are among the items that could shape sentiment on Bristol-Myers Squibb ahead of the open. The September 10, 2026 options note from MarketBeat highlighted a large volume of put contracts opened on NYSE:BMY, which may keep risk management and hedging flows in focus today as traders reassess downside protection. In parallel, an analyst update dated September 10, 2026 from GuruFocus reported that HSBC had maintained its rating on Bristol-Myers Squibb while lifting its price target to USD 65.00, a move that keeps attention on valuation and forward earnings expectations. These factors, together with the broader healthcare sector’s reaction to macro data and interest rate expectations, frame the backdrop for Bristol-Myers Squibb stock as it heads into today’s United States session.
